Zobrazeno 1 - 4
of 4
pro vyhledávání: '"O'Connor LO"'
Autor:
Fok JHL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Ramos-Montoya A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Vazquez-Chantada M; Mechanistic Biology and Profiling, Discovery Sciences, Oncology R&D, AstraZeneca, Cambridge, UK., Wijnhoven PWG; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Follia V; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., James N; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Farrington PM; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Karmokar A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Willis SE; Translational Science, Oncology R&D, AstraZeneca, Cambridge, UK., Cairns J; Quantitative Biology, Discovery Science, Oncology R&D, AstraZeneca, Cambridge, UK., Nikkilä J; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Beattie D; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK., Lamont GM; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK., Finlay MRV; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK., Wilson J; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., Smith A; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor LO; Translational Science, Oncology R&D, AstraZeneca, Cambridge, UK., Ling S; Mechanistic Biology and Profiling, Discovery Sciences, Oncology R&D, AstraZeneca, Cambridge, UK., Fawell SE; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Hollingsworth SJ; Oncology Business Unit, AstraZeneca, Cambridge, UK., Dean E; Oncology Translational Medicine Unit, Early Clinical Development, Oncology R&D, AstraZeneca, Cambridge, UK., Goldberg FW; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK., Davies BR; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Cadogan EB; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK. elaine.cadogan@astrazeneca.com.
Publikováno v:
Nature communications [Nat Commun] 2019 Nov 07; Vol. 10 (1), pp. 5065. Date of Electronic Publication: 2019 Nov 07.
Autor:
Young LA; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., O'Connor LO; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., de Renty C; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Veldman-Jones MH; Bioscience, Oncology R&D, AstraZeneca, Alderley Park, United Kingdom., Dorval T; Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Wilson Z; Bioscience, Oncology R&D, AstraZeneca, Alderley Park, United Kingdom., Jones DR; Bioscience, Oncology R&D, AstraZeneca, Alderley Park, United Kingdom., Lawson D; Bioscience, Oncology R&D, AstraZeneca, Boston, MA., Odedra R; Bioscience, Oncology R&D, AstraZeneca, Alderley Park, United Kingdom., Maya-Mendoza A; Danish Cancer Society Research Centre, Copenhagen, Denmark., Reimer C; Bioscience, Oncology R&D, AstraZeneca, Boston, MA., Bartek J; Danish Cancer Society Research Centre, Copenhagen, Denmark.; Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden., Lau A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. mark.j.oconnor@astrazeneca.com.
Publikováno v:
Cancer research [Cancer Res] 2019 Jul 15; Vol. 79 (14), pp. 3762-3775. Date of Electronic Publication: 2019 May 23.
Autor:
Fornari C; Safety and ADME Translational Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK., O'Connor LO; Oncology Translational Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK., Yates JWT; DMPK, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK., Cheung SYA; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, Cambridge, UK., Jodrell DI; CRUK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK., Mettetal JT; Safety and ADME Translational Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA., Collins TA; Safety and ADME Translational Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2018 Oct; Vol. 104 (4), pp. 644-654. Date of Electronic Publication: 2018 May 01.